Korean Society of Nephrology 2022 recommendations on controversial issues in diagnosis and management of hyponatremia

키워드

참고문헌 (88)

1. Spasovski G, "Clinical practice guideline on diagnosis and treatment of hyponatraemia", Nephrol Dial Transplant, 29(Suppl 2), pp.i1~i39 (2014)
2. Verbalis JG, "Diagnosis, evaluation, and treatment of hyponatremia : expert panel recommendations", Am J Med, 126(10 Suppl 1), pp.S1~S42 (2013)
3. Hoorn EJ, "Diagnosis and treatment of hyponatremia : compilation of the guidelines", J Am Soc Nephrol, 28, pp.1340~1349 (2017)
4. Hillier TA, "Hyponatremia : evaluating the correction factor for hyperglycemia", Am J Med, 106, pp.399~403 (1999)
5. Filippatos TD, "Hyponatremia in the elderly : challenges and solutions", Clin Interv Aging, 12, pp.1957~1965 (2017)
6. Ebell MH, "A systematic review of the efficacy and safety of desmopressin for nocturia in adults", J Urol, 192, pp.829~835 (2014)
7. Decaux G, "Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone", Clin J Am Soc Nephrol, 3, pp.1175~1184 (2008)
8. Fenske W, "Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics", J Clin Endocrinol Metab, 93, pp.2991~2997 (2008)
9. Nigro N, "Copeptin levels and commonly used laboratory parameters in hospitalised patients with severe hypernatraemia : the"Co-MED study"", Crit Care, 22, pp.33~ (2018)
10. Bassi V, "The role of fractional excretion of uric acid in the differential diagnosis of hypotonic hyponatraemia in patients with diuretic therapy", Cureus, 12, pp.e7762~ (2020)
11. Musch W, "Utility and limitations of biochemical parameters in the evaluation of hyponatremia in the elderly", Int Urol Nephrol, 32, pp.475~493 (2001)
12. Musch W, "Combined fractional excretion of sodium and urea better predicts response to saline in hyponatremia than do usual clinical and biochemical parameters", Am J Med, 99, pp.348~355 (1995)
13. Maesaka JK, "Determining fractional urate excretion rates in hyponatremic conditions and improved methods to distinguish cerebral", renal salt wasting from the syndrome of inappropriate secretion of antidiuretic hormone, 2018, pp.5, 319~
14. Choi HK, "Antihypertensive drugs and risk of incident gout among patients with hypertension : population based case-control study", BMJ, 344, pp.d8190~ (2012)
15. Fenske W, "Copeptin in the differential diagnosis of hyponatremia", J Clin Endocrinol Metab, 94, pp.123~129 (2009)
16. Go Suryeong, "Association between copeptin levels and treatment responses to hypertonic saline infusion in patients with symptomatic hyponatremia: a prospective cohort study", Kidney Research and Clinical Practice, 40(3), pp.371~382 (2021), 대한신장학회[DOI]
17. Baek SH, "Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies of hypertonic saline for patients with symptomatic hyponatremia : the SALSA randomized clinical trial", JAMA Intern Med, 181, pp.81~92 (2021)
18. Garrahy A, "Continuous versus bolus infusion of hypertonic saline in the treatment of symptomatic hyponatremia caused by SIAD", J Clin Endocrinol Metab, 104, pp.3595~3602 (2019)
19. Waikar SS, "Mortality after hospitalization with mild, moderate, and severe hyponatremia", Am J Med, 122, pp.857~865 (2009)
20. Doshi SM, "Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes", Am J Kidney Dis, 59, pp.222~228 (2012)
21. Kovesdy CP, "Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure", Circulation, 125, pp.677~684 (2012)
22. Choi JS, "Prognostic impact of hyponatremia occurring at various time points during hospitalization on mortality in patients with acute myocardial infarction", Medicine(Baltimore), 96, pp.e7023~ (2017)
23. Jujo K, "Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure", ESC Heart Fail, 3, pp.177~188 (2016)
24. Tanaka T, "Addition of tolvaptan compared with increased dose of furosemide in heart failure patients with chronic kidney disease under furosemide treatment", Circ Rep, 1, pp.35~41 (2018)
25. Tominaga N, "Effects of tolvaptan addition to furosemide in normo-and hyponatremia patients with heart failure and chronic kidney disease stages G3b-5 : a subanalysis of the K-STAR Study", Am J Nephrol, 46, pp.417~426 (2017)
26. Felker GM, "Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure", J Am Coll Cardiol, 69, pp.1399~1406 (2017)
27. Kimura K, "Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure", J Cardiol, 67, pp.399~405 (2016)
28. Kin H, "Renoprotective effect of tolvaptan in patients with new-onset acute heart failure", ESC Heart Fail, 7, pp.1764~1770 (2020)
29. Konstam MA, "Short-term effects of tolvaptan in patients with acute heart failure and volume overload", J Am Coll Cardiol, 69, pp.1409~1419 (2017)
30. Matsue Y, "Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction", J Card Fail, 22, pp.423~432 (2016)
31. Shanmugam E, "Effect of tolvaptan on acute heart failure with hyponatremia : a randomized, double blind, controlled clinical trial", Indian Heart J, 68(Suppl 1), pp.S15~S21 (2016)
32. Ellison DH, "Clinical practice : the syndrome of inappropriate antidiuresis", N Engl J Med, 356, pp.2064~2072 (2007)
33. Rondon-Berrios H, "Mild chronic hyponatremia in the ambulatory setting : significance and management", Clin J Am Soc Nephrol, 10, pp.2268~2278 (2015)
34. Berl T, "Oral tolvaptan is safe and effective in chronic hyponatremia", J Am Soc Nephrol, 21, pp.705~712 (2010)
35. Bhandari S, "A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans", Clin Endocrinol(Oxf), 86, pp.761~771 (2017)
36. Nagler EV, "Interventions for chronic non-hypovolaemic hypotonic hyponatraemia", Cochrane Database Syst Rev, 6, pp.CD010965~ (2018)
37. Goldberg A, "Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction", Arch Intern Med, 166, pp.781~786 (2006)
38. Torres VE, "Tolvaptan in patients with autosomal dominant polycystic kidney disease", N Engl J Med, 367, pp.2407~2418 (2012)
39. Abraham WT, "Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia", Kidney Int, 82, pp.1215~1222 (2012)
40. Annane D, "Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia", Am J Med Sci, 337, pp.28~36 (2009)
41. Ghali JK, "Efficacy and safety of oral conivaptan : a V1A", V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia, 2006, pp.91, 2145~2152
42. Gheorghiade M, "Vasopressin v(2)receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia", Am J Cardiol, 97, pp.1064~1067 (2006)
43. Abraham WT, "Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia", Kidney Int, 82, pp.1223~1230 (2012)
44. Chen S, "Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH", J Clin Pharmacol, 54, pp.1362~1367 (2014)
45. Koren MJ, "Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia", Am J Health Syst Pharm, 68, pp.818~827 (2011)
46. Salahudeen AK, "Tolvaptan in hospitalized cancer patients with hyponatremia : a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety", Cancer, 120, pp.744~751 (2014)
47. Schrier RW, "Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia", N Engl J Med, 355, pp.2099~2112 (2006)
48. Soupart A, "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan(SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist", Clin J Am Soc Nephrol, 1, pp.1154~1160 (2006)
49. Wong F, "A vasopressin receptor antagonist(VPA-985)improves serum sodium concentration in patients with hyponatremia : a multicenter, randomized, placebo-controlled trial", Hepatology, 37, pp.182~191 (2003)
50. Perianayagam A, "DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia", Clin J Am Soc Nephrol, 3, pp.331~336 (2008)
51. Sood L, "Hypertonic saline and desmopressin : a simple strategy for safe correction of severe hyponatremia", Am J Kidney Dis, 61, pp.571~578 (2013)
52. MacMillan TE, "Desmopressin to prevent rapid sodium correction in severe hyponatremia : a systematic review", Am J Med, 128, pp.1362~ (2015)
53. MacMillan TE, "Outcomes in severe hyponatremia treated with and without desmopressin", Am J Med, 131, pp.317~ (2018)
54. Ward FL, "The role of desmopressin in the management of severe, hypovolemic hyponatremia : a single-center, comparative analysis", Can J Kidney Health Dis, 5, pp.2054358118761051~ (2018)
55. Lohani S, "Hyponatremia in patients with traumatic brain injury : etiology, incidence, and severity correlation", World Neurosurg, 76, pp.355~360 (2011)
56. Yumoto T, "Prevalence, risk factors, and short-term consequences of traumatic brain injury-associated hyponatremia", Acta Med Okayama, 69, pp.213~218 (2015)
57. Barkas F, "Hyponatremia in acute stroke : to treat or not to treat?", J Stroke Cerebrovasc Dis, 28, pp.104421~ (2019)
58. Mapa B, "Impact of hyponatremia on morbidity, mortality, and complications after aneurysmal subarachnoid hemorrhage : a systematic review", World Neurosurg, 85, pp.305~314 (2016)
59. Sherlock M, "Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients", Postgrad Med J, 85, pp.171~175 (2009)
60. Sivakumar V, "Management of neurosurgical patients with hyponatremia and natriuresis", Neurosurgery, 34, pp.269~274 (1994)
61. Hasan D, "Effect of fluid intake and antihypertensive treatment on cerebral ischemia after subarachnoid hemorrhage", Stroke, 20, pp.1511~1515 (1989)
62. Wijdicks EF, "Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms : is fluid restriction harmful?", Ann Neurol, 17, pp.137~140 (1985)
63. Rahman M, "Hyponatremia in neurosurgical patients : clinical guidelines development", Neurosurgery, 65, pp.925~936 (2009)
64. Hasan D, "Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage", Stroke, 20, pp.1156~1161 (1989)
65. Misra UK, "Safety and efficacy of fludrocortisone in the treatment of cerebral salt wasting in patients with tuberculous meningitis : a randomized clinical trial", JAMA Neurol, 75, pp.1383~1391 (2018)
66. Feld LG, "Clinical practice guideline : maintenance intravenous fluids in children", Pediatrics, 142, pp.e20183083~ (2018)
67. Neilson J, "Intravenous fluids in children and young people : summary of NICE guidance", BMJ, 351, pp.h6388~ (2015)
68. Almeida HI, "The effect of NaCl 0.9% and NaCl 0.45% on sodium, chloride, and acid-base balance in a PICU population", J Pediatr(Rio J), 91, pp.499~505 (2015)
69. Bagri NK, "Isotonic versus hypotonic intravenous maintenance fluids in children : a randomized controlled trial", Indian J Pediatr, 86, pp.1011~1016 (2019)
70. Balasubramanian K, "Isotonic versus hypotonic fluid supplementation in term neonates with severe hyperbilirubinemia : a double-blind, randomized, controlled trial", Acta Paediatr, 101, pp.236~241 (2012)
71. Choong K, "Hypotonic versus isotonic maintenance fluids after surgery for children : a randomized controlled trial", Pediatrics, 128, pp.857~866 (2011)
72. Coulthard MG, "A randomised controlled trial of Hartmann’s solution versus half normal saline in postoperative paediatric spinal instrumentation and craniotomy patients", Arch Dis Child, 97, pp.491~496 (2012)
73. Dathan K, "Comparison of isotonic versus hypotonic intravenous fluid for maintenance fluid therapy in neonates more than or equal to 34 weeks of gestational age : a randomized clinical trial", J Matern Fetal Neonatal Med (2021)[DOI]
74. Friedman JN, "Comparison of isotonic and hypotonic intravenous maintenance fluids : a randomized clinical trial", JAMA Pediatr, 169, pp.445~451 (2015)
75. Kannan L, "Intravenous fluid regimen and hyponatraemia among children : a randomized controlled trial", Pediatr Nephrol, 25, pp.2303~2309 (2010)
76. Kumar M, "Isotonic versus hypotonic saline as maintenance intravenous fluid therapy in children under 5 years of age admitted to general paediatric wards : a randomised controlled trial", Paediatr Int Child Health, 40, pp.44~49 (2020)
77. Lehtiranta S, "Risk of electrolyte disorders in acutely ill children receiving commercially available plasmalike isotonic fluids : a randomized clinical trial", JAMA Pediatr, 175, pp.28~35 (2021)
78. McNab S, "140 mmol", L of sodium versus 77 mmol, Lancet, pp.2015, 385[DOI]
79. Montanana PA, "The use of isotonic fluid as maintenance therapy prevents iatrogenic hyponatremia in pediatrics : a randomized, controlled open study", Pediatr Crit Care Med, 9, pp.589~597 (2008)
80. Neville KA, "Prevention of hyponatremia during maintenance intravenous fluid administration : a prospective randomized study of fluid type versus fluid rate", J Pediatr, 156, pp.313~319 (2010)
81. Pemde HK, "Isotonic intravenous maintenance fluid reduces hospital acquired hyponatremia in young children with central nervous system infections", Indian J Pediatr, 82, pp.13~18 (2015)
82. Ramanathan S, "Isotonic versus hypotonic parenteral maintenance fluids in very severe pneumonia", Indian J Pediatr, 83, pp.27~32 (2016)
83. Rey C, "Hypotonic versus isotonic maintenance fluids in critically ill children : a multicenter prospective randomized study", Acta Paediatr, 100, pp.1138~1143 (2011)
84. Shamim A, "Safety and efficacy of isotonic(0. 9%)vs. hypotonic(0. 18%)saline as maintenance intravenous fluids in children : a randomized controlled trial", Indian Pediatr, 51, pp.969~974 (2014)
85. Torres SF, "Hypotonic and isotonic intravenous maintenance fluids in hospitalised paediatric patients : a randomised controlled trial", BMJ Paediatr Open, 3, pp.e000385~ (2019)
86. Chromek M, "Hyponatraemia despite isotonic maintenance fluid therapy : a time series intervention study", Arch Dis Child, 106, pp.491~495 (2020)
87. Velasco P, "Hospital-acquired hyponatremia : does the type of fluid therapy affect children admitted to intensive care?", Rev Chil Pediatr, 89, pp.42~50 (2018)
88. Tuzun F, "Comparison of isotonic and hypotonic intravenous fluids in term newborns : is it time to quit hypotonic fluids", J Matern Fetal Neonatal Med, 35, pp.356~361 (2022)

관련 논문AI추천